Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio
Why Pfizer Is a Turnaround Play Worth Watching in 2026
In this episode of Stock Picking with Fexingo, Lucas and Luna dig into the case for Pfizer as a potential turnaround stock in mid-2026. With shares trading around $25, down from pandemic highs, they discuss the company's pipeline catalysts, cost-cutting efforts, and the role of its dividend in a volatile market. Lucas explains why the market's pessimism might be overdone, while Luna pushes back on the risk of patent cliffs and lack of blockbuster growth. They reference the Russell 2000's recent weakness and value stock outperformance to frame the broader backdrop. A focused…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.